Discovery and development of anti-angiogenic peptides: A structural link

被引:24
作者
Ruud P.M. Dings
Irina Nesmelova
Arjan W. Griffioen
Kevin H. Mayo
机构
[1] Dept. Biochem., Molec. Bio./Biophys., Univ. of Minnesota Hlth. Sci. Center, Minneapolis, MN
[2] Department of Internal Medicine, University Hospital, Maastricht University, Maastricht
[3] Dept. Biochem., Molec. Bio./Biophys., Univ. of Minnesota Hlth. Sci. Center, Minneapolis, MN 55455
基金
美国国家卫生研究院;
关键词
Angiogenesis inhibition; Angiostatic peptides; Angiostatic proteins; Designer peptides and review;
D O I
10.1023/B:AGEN.0000011730.94233.06
中图分类号
学科分类号
摘要
Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.
引用
收藏
页码:83 / 91
页数:8
相关论文
共 100 条
[31]  
Rehn M., Veikkola T., Kukk-Valdre E., Et al., Interaction of endostatin with integrins implicated in angiogenesis, Proc Natl Acad Sci USA, 98, pp. 1024-1029, (2001)
[32]  
Jiang L., Jha V., Dhanabal M., Et al., Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin, Am J Physiol, 280, (2001)
[33]  
Hohenester E., Sasaki T., Olsen B.R., Timpl R., Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution, EMBO J, 17, pp. 1656-1664, (1998)
[34]  
Graves B.J., Crowther R.L., Chandran C., Et al., Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains, Nature, 367, pp. 532-538, (1994)
[35]  
Dixelius J., Larsson H., Sasaki T., Et al., Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis, Blood, 95, pp. 3403-3411, (2000)
[36]  
Timpl R., Wiedemann H., Van DeIden V., Et al., A network model for the organization of type IV collagen molecules in basement membranes, Eur J Biochem, 120, pp. 203-211, (1981)
[37]  
Maeshima Y., Colorado P.C., Torre A., Et al., Distinct antitumor properties of a type IV collagen domain derived from basement membrane, J Biol Chem, 275, pp. 21340-21348, (2000)
[38]  
Han J., Ohno N., Pasco S., Et al., A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells, J Biol Chem, 272, pp. 20395-20401, (1997)
[39]  
Maeshima Y., Colorado P.C., Kalluri R., Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties, J Biol Chem, 275, pp. 23745-23750, (2000)
[40]  
Maeshima Y., Manfredi M., Reimer C., Et al., Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin, J Biol Chem, 276, pp. 1524-1528, (2001)